search
Back to results

Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol (CANTAPOR)

Primary Purpose

Female Infertility, Ovarian Insufficiency

Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
High Dose Clomiphencitrat
Low Dose Clomiphencitrat
High Dose Placebo
Low dose Placebo
Sponsored by
University Hospital, Basel, Switzerland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Female Infertility focused on measuring female infertility, poor ovarian response, controlled ovarian hyperstimulation, IVF, Antagonist protocol

Eligibility Criteria

18 Years - 43 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Age: >18 years < 43 years
  • BMI: ≥ 18 ≤ 32 kg/m2
  • Poor responder as defined by ESHRE working group

Exclusion Criteria:

  • Age < 18 und > 43 years
  • Pregnancy
  • Breast feeding
  • Uterine conditions interfering with endometrial proliferation and embryo implantation (submucous fibroids or polyps)
  • Women diagnosed with PCOS according to the Rotterdam criteria
  • Hyperprolactinaemia - untreated
  • Both ovaries not accessible transvaginally for oocyte pick up
  • Ovarian cysts of unclear dignity
  • Evidence of hydrosalpinx on ultrasound
  • Clinically significant severe systemic disease that are incompatible with pregnancy
  • Known or suspected hypersensitivity to the active substances (gonadotrophins, ganirelix, progesterone, clomiphencitrate)
  • Untreated thyroid or adrenal disorders
  • Bleeding disorders
  • Cancer
  • Severe renal or hepatic dysfunction
  • Necessity to take medication that could influence ovarian stimulation
  • History of OHSS in prior IVF cycle

Sites / Locations

  • University Hospital Basel

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Placebo Comparator

Arm Label

High Dose Clomiphencitrat

Low Dose Clomiphencitrat

High Dose Placebo

Low Dose Placebo

Arm Description

450 IU Merional® plus 100mg Serophene®

150 IU Merional® plus 100mg Serophene®

450 IU Merional® plus Placebo

150 IU Merional® plus Placebo

Outcomes

Primary Outcome Measures

number of collected oocytes

Secondary Outcome Measures

Implantation rate

Full Information

First Posted
April 5, 2012
Last Updated
December 3, 2018
Sponsor
University Hospital, Basel, Switzerland
search

1. Study Identification

Unique Protocol Identification Number
NCT01577472
Brief Title
Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol
Acronym
CANTAPOR
Official Title
Prospective Randomized Phase IV Study Comparing the Effect of Adding Clomiphencitrate Versus Placebo to a High Dose Versus a Minimal Dose GnRH Antagonist Protocol on the Number of Oocytes Collected From Women That Are Poor Responders
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
August 2013 (Actual)
Primary Completion Date
November 14, 2017 (Actual)
Study Completion Date
November 14, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to assess the oocyte yield of infertile women with suspected or known poor ovarian reserve (POR) undergoing a GnRH antagonist protocol for IVF with Merional® starting either with a low (150 IU) or a high dose (450 IU) and adding 100mg of CC (Serophene®) in the early follicular phase of the stimulation (day 3 to 7). To date no RCT has been conducted to compare the reproductive outcome of patients with POR as defined by the ESHRE Bologna criteria after controlled ovarian hyperstimulation with HMG in an GnRH antagonist protocol using low doses versus high doses of HMG and adding CC versus placebo. We hypothesize that adding 100 mg of CC on day 3-7 to a HMG antagonist protocol will lead to an additional increment of endogenous GT thus increasing the oocytes yield after controlled ovarian stimulation due to higher endogenous gonadotropin secretion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Female Infertility, Ovarian Insufficiency
Keywords
female infertility, poor ovarian response, controlled ovarian hyperstimulation, IVF, Antagonist protocol

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
117 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High Dose Clomiphencitrat
Arm Type
Active Comparator
Arm Description
450 IU Merional® plus 100mg Serophene®
Arm Title
Low Dose Clomiphencitrat
Arm Type
Active Comparator
Arm Description
150 IU Merional® plus 100mg Serophene®
Arm Title
High Dose Placebo
Arm Type
Placebo Comparator
Arm Description
450 IU Merional® plus Placebo
Arm Title
Low Dose Placebo
Arm Type
Placebo Comparator
Arm Description
150 IU Merional® plus Placebo
Intervention Type
Drug
Intervention Name(s)
High Dose Clomiphencitrat
Intervention Description
100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Intervention Type
Drug
Intervention Name(s)
Low Dose Clomiphencitrat
Intervention Description
100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Intervention Type
Drug
Intervention Name(s)
High Dose Placebo
Intervention Description
Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Intervention Type
Drug
Intervention Name(s)
Low dose Placebo
Intervention Description
Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
Primary Outcome Measure Information:
Title
number of collected oocytes
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Implantation rate
Time Frame
1 year

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
43 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age: >18 years < 43 years BMI: ≥ 18 ≤ 32 kg/m2 Poor responder as defined by ESHRE working group Exclusion Criteria: Age < 18 und > 43 years Pregnancy Breast feeding Uterine conditions interfering with endometrial proliferation and embryo implantation (submucous fibroids or polyps) Women diagnosed with PCOS according to the Rotterdam criteria Hyperprolactinaemia - untreated Both ovaries not accessible transvaginally for oocyte pick up Ovarian cysts of unclear dignity Evidence of hydrosalpinx on ultrasound Clinically significant severe systemic disease that are incompatible with pregnancy Known or suspected hypersensitivity to the active substances (gonadotrophins, ganirelix, progesterone, clomiphencitrate) Untreated thyroid or adrenal disorders Bleeding disorders Cancer Severe renal or hepatic dysfunction Necessity to take medication that could influence ovarian stimulation History of OHSS in prior IVF cycle
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rebecca E Moffat, MD
Organizational Affiliation
University Hospital Basel, Women's Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Basel
City
Basel
ZIP/Postal Code
4031
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
33367742
Citation
Moffat R, Hansali C, Schoetzau A, Ahler A, Gobrecht U, Beutler S, Raggi A, Sartorius G, De Geyter C. Randomised controlled trial on the effect of clomiphene citrate and gonadotropin dose on ovarian response markers and IVF outcomes in poor responders. Hum Reprod. 2021 Mar 18;36(4):987-997. doi: 10.1093/humrep/deaa336.
Results Reference
derived

Learn more about this trial

Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol

We'll reach out to this number within 24 hrs